ArticleMikrochimica acta2025
Ultra-fast, palm-sized platform for visual point-of-care virus detection using convective PCR with gold nanoparticle probes.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Convective PCR (cPCR) offers rapid and efficient DNA amplification in as little as 10 min, presenting a promising alternative to traditional PCR. However, current palm-sized cPCR devices fail to achieve one-pot visual detection, limiting their utility for point-of-care testing. Here, we present a visual convective PCR (Vis-cPCR) assay that integrates reverse transcription, ultra-fast cPCR, nested invasive reactions, and gold nanoparticle probes (AuNPs)-based colorimetric detection into a single-tube, one-pot system. This assay eliminates the need for time-consuming nucleic acid extraction and purification by employing a room-temperature chemical lysis step, which rapidly releases viral RNA from pharyngeal swabs in just 2 min and is fully compatible with downstream detection. The palm-sized cPCR device enables the entire process-including reverse transcription, DNA amplification, amplicon identification, and visual signal generation-to be completed in approximately 30 min. The Vis-cPCR assay demonstrates high sensitivity (as low as 10 copies) and specificity for detecting a panel of viruses, including SARS-CoV-2, influenza A/B, western equine encephalitis virus, tick-borne encephalitis virus, chikungunya virus, and Zika virus. Validation using 30 clinical pharyngeal swab samples and 42 artificially prepared arboviral RNA samples showed 100% agreement with RT-qPCR results. By combining rapid sample preparation, ultra-fast amplification, and visual detection, Vis-cPCR represents a significant advancement in point-of-care diagnostics, offering a simple, cost-effective, and highly efficient tool for on-site pathogen screening in resource-limited settings and emergency situations.
Indexed as
Identifiers
40760206What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.